Project: Development of Isogenic Control Induced Pluripotent Stem Cell (iPSC) Models of OCNDS

Sampled is a leading biotechnology company in the field of biobanking and bioprocessing, aiming to turn precious patient samples into renewable resources to extend research possibilities.

Grant Details:

Project funded for 1 year starting in 2023 for $34,793.

Aims of Grant:

The CSNK2A1 Foundation has contracted Sampled to create and store isogenic controls for OCNDS patient samples. In rare disease research, it is critical to compare patient samples to controls that are as similar as possible to the original sample except for the disease-causing mutation – termed isogenic controls. Sampled will revert OCNDS-causing mutations in patient samples through CRISPR-Cas9 gene-editing technology back to typical human sequences and will store these samples for use by future researchers. This will create an essential resource for OCNDS researchers to study both the basic molecular biology of and possible treatments for OCNDS.